Skip to main content
Haemato AG logo

Haemato AG — Investor Relations & Filings

Ticker · HAEK ISIN · DE000A289VV1 LEI · 529900Q3CGRYVCW7E340 F Wholesale and retail trade
Open in API
Filings indexed 188 across all filing types
Latest filing 2021-03-29 Capital/Financing Update
Country DE Germany
Listing F HAEK

About Haemato AG

https://haemato.de/en/start.html

Haemato AG is a pharmaceutical company focused on the specialty pharma market, concentrating on treatments for chronic diseases and high-priced therapies. The company's business activities include the development, acquisition, licensing, and distribution of a product portfolio that comprises innovative patent-protected medicines, biosimilars, and generics. The portfolio also extends to narcotics, including cannabis products, as well as over-the-counter (OTC) products and special cosmetics. Haemato AG's primary therapeutic areas of focus are HIV/AIDS, neurology, oncology, rheumatology, and ophthalmology.

Recent filings

Filing Released Lang Actions
HAEMATO AG successfully completes capital increase
Capital/Financing Update Classification · 99% confidence The document is an 'Ad-hoc' announcement dated March 29, 2021, explicitly stating that HAEMATO AG 'successfully completes capital increase'. It details the issuance of new shares, the placement price, and the intended use of proceeds (€14.7 million). This content directly relates to fundraising, financing activities, and changes in capital structure. This aligns perfectly with the definition for 'Capital/Financing Update' (Code: CAP). It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), as it concerns a specific corporate action.
2021-03-29 English
HAEMATO AG plans cash capital increase to finance private label business
Share Issue/Capital Change Classification · 99% confidence The document is an 'Ad-hoc' announcement dated March 24, 2021, explicitly stating that 'HAEMATO AG plans cash capital increase to finance private label business'. It details the resolution to increase share capital by up to 10% against cash contributions, issuing new shares. This action directly relates to fundraising, financing activities, and changes in the capital structure. Therefore, it fits the definition of 'Capital/Financing Update' (CAP). It is not an Annual Report (10-K), an Earnings Release (ER), or a Dividend Notice (DIV).
2021-03-24 English
HAEMATO AG: HAEMATO PHARM GmbH as a subsidiary of HAEMATO AG receives a special approval according to 11 Abs. 1 MPG
Regulatory Filings Classification · 100% confidence The document is an 'Ad-hoc' announcement dated March 23, 2021, disclosing inside information according to MAR (Regulation (EU) No 596/2014). The content details a subsidiary receiving a 'special approval' from a regulatory body (BfArM) for a medical device (antigen rapid test). This is a specific corporate event disclosure that is not a standard periodic report (like 10-K or IR) or a financial result announcement (ER). Since it is a specific regulatory/legal event disclosure that doesn't fit the defined categories like DIRS, TAR, or CAP, and it is a direct announcement rather than a report publication announcement (RPA), the most appropriate fallback category is Regulatory Filings (RNS), which covers general regulatory announcements.
2021-03-23 English
HAEMATO AG: Patrick Brenske to be the sole member of the Executive Board of HAEMATO AG in the future
Board/Management Information Classification · 100% confidence The document is an 'Ad-hoc' announcement dated February 1, 2021, disclosing information under MAR Article 17. The core content details a change in the Executive Board of HAEMATO AG, specifically that Patrick Brenske will become the sole member following Daniel Kracht's departure. This type of announcement, concerning changes in senior management or the board of directors, directly corresponds to the definition of 'Board/Management Information'.
2021-02-01 English
HAEMATO AG: HAEMATO AG acquires 'M1 Aesthetics GmbH' from M1 Kliniken AG - Contribution of the company within the scope of a capital increase in kind of HAEMATO AG
Share Issue/Capital Change Classification · 99% confidence The document is a news release dated December 15, 2020, announcing that HAEMATO AG is acquiring 'M1 Aesthetics GmbH' from M1 Kliniken AG via a capital increase in kind. Key phrases like 'Takeover/Capital Increase', 'acquisition of all shares', and 'capital increase through contribution in kind' strongly indicate a transaction related to corporate structure and financing. This aligns directly with the definition of 'Capital/Financing Update' (CAP). Although it involves a takeover, the primary mechanism described is the capital increase to facilitate the transaction, making CAP the most precise fit over TAR (Merger/Takeover Activity), which usually implies a tender offer or full merger announcement. Since it is a formal announcement of a significant corporate action involving share issuance and acquisition, it is not a general regulatory filing (RNS) or a report itself.
2020-12-15 English
HAEMATO AG: HAEMATO AG acquires 'M1 Aesthetics GmbH' from M1 Kliniken AG - Contribution of the company within the scope of a capital increase in kind of HAEMATO AG
M&A Activity Classification · 100% confidence The document is an 'Ad-hoc' announcement dated December 15, 2020, disclosing an 'inside information acc. to Article 17 MAR'. The core content details the acquisition of 'M1 Aesthetics GmbH' by HAEMATO AG through a capital increase in kind. This transaction involves a takeover/merger activity and a subsequent capital structure change. Since the primary event is the acquisition/takeover proposal, the most fitting category is 'M&A Activity' (TAR). While it involves a capital increase (CAP), the context is driven by the takeover, making TAR more specific. It is not a standard regulatory report (10-K, IR) but an announcement of a major corporate action.
2020-12-15 English

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.